Procyrion Wins 2017 People’s Choice Award at the American Heart Association Health Tech Competition

press release

HOUSTON, TX (November 13, 2017) -  Houston heart pump developer Procyrion Inc. today announced they have won the People’s Choice Award from the American Heart Association’s (AHA) during the 2017 Health Tech Competition with their ground-breaking technology, Aortix™, a catheter-based circulatory support device. The competition recognizes innovative healthcare solutions that improve patient outcomes for heart health.

2017 People's Choice Award

Procyrion’s winning technology, Aortix™, which is thinner than a #2 pencil, is the first catheter-based heart pump designed specifically for the ambulatory treatment of NYHA Class III-IVa heart failure patients who are too sick for medication alone, but not sick enough for risky surgical interventions (e.g. LVAD or transplant). The small but powerful micro pump is placed downstream of the heart in a simple cath-lab procedure and works to support heart function by accelerating native blood flow.

“We’re passionate about Aortix and the impact it will have on the millions suffering from chronic heart failure,” said Benjamin A. Hertzog, Ph.D., CEO of Procyrion. “The opportunity to showcase our technology was extremely valuable and being chosen by such an esteemed audience further validates our work and the need for improved patient health”

Eight finalists presented a wide range of innovative healthcare solutions to a panel of judges and an audience of cardiologists at the AHA’s Scientific Sessions 2017 in Anaheim, CA on November 13. With over 18,000 scientist and healthcare professionals in attendance, the Annual Scientific Sessions is the AHA’s largest event. The People’s Choice Award was given to Procyrion based on votes from cardiologists in attendance and is awarded to the company with the most innovative approach to improving patient outcomes.


To see the full list of finalists please visit the AHA website here.



Houston-based medical device firm Procyrion, Inc. is developing the first catheter-deployed, intra-aortic pump for ambulatory use.  The device is designed to rest and heal the heart by reducing afterload while simultaneously improving blood flow to vital organs. This groundbreaking cardiology tool, conceived by cardiologist Dr. Reynolds M. Delgado, III, medical director of Mechanical Support Devices in Heart Failure at the Texas Heart Institute, is expected to provide a minimally invasive treatment option for millions of chronic heart failure patients.  For more information, visit or call 713.579.9227.


# # #



Dana Summers

Penman PR



Read More